Clinical Trial Update: Low-dose Interleukin-2 in Combination With Standard Therapy on Idiopathic Inflammatory Myopathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose interleukin-2 in combination with standard therapy for inflammatory myopathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Myopathy

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Inflammatory Myopathy | Phase 2 | Status: UNKNOWN